CHA HEALTH SYSTEMS has been a pioneer and global leader in the treatment of infertility since 1985.
Throughout our 20-year history, CHA HEALTH SYSTEMS has received worldwide recognition and accolades for our clinical research and scientific advancements in the field of obstetrics/
gynecology, reproductive endocrinology and infertility.

One of our most significant achievements is the development of our exclusive, proprietary
vitrification or freezing technology by our CHA BIOTECH research team to successfully
cryopreserve human oocytes (eggs).

90% survival rate of thawed oocytes and 65% pregnancy rate
Researchers first pioneered CHA BIOTECH's oocyte vitrification technology in 1998 and
succeeded in bringing the first test-tube baby into the world in 1999.
Years later, our research team further optimized this technique by employing slush nitrogen
which improved the outcome to an astounding 90% survival rate and 65% pregnancy rate.
CHA BIOTECH subsequently received several awards for their research efforts from the
American Society of Reproductive Medicine (ASRM) and International Federation of Fertility
Society.
With the success of its oocyte vitrification technology, in 2002, CHA BIOTECH established public and private oocyte banks in Korea followed by the first commercial oocyte bank in the U.S.

Oocyte (egg) banking:
0 From practical options for fertility to the promising benefits for stem cell research
We believe our innovative oocyte vitrification technology and oocyte banking program offer
great promise and opportunity in the preservation of eggs and embryos not only for fertility
treatment but also for stem cell research. Oocyte banking offers hope to cancer patients
whose chances of having a baby are threatened or compromised by cancer treatments.

Women who are choosing to delay pregnancy are afforded a viable option to preserve their
ability to have a baby in the future. And women relying on donor oocytes for fertility treatment are no longer inconvenienced with the challenges of synchronization of cycles between the
donor and recipient. For stem cell research, oocyte banking affords scientists with a convenient and reliable source and supply of oocytes for research when they need it.

This technology also gives researchers the opportunity to detect various diseases in donor
oocytes and allows for the screening of eggs prior to clinical use.

And ultimately, our oocyte vitrification technology will be the means by which the supply of
eggs for the production of patient-specific stem cells will be preserved for the treatment of
diseases of individual patients.